Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase III Study of OMS906 in ''switch-over" design in PNH patients who have had an unsatisfactory response to ravulizumab

Next Previous
Search
Trial Profile

A phase III Study of OMS906 in ''switch-over" design in PNH patients who have had an unsatisfactory response to ravulizumab

Status: Planning
Phase of Trial: Phase III

Latest Information Update: 10 Apr 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Zaltenibart (Primary)
  • Indications Paroxysmal nocturnal haemoglobinuria
  • Focus Therapeutic Use

    • Most Recent Events

    • 26 Mar 2025 According to an Omeros Corporation media release, site activation has begun in Phase 3 development program evaluating zaltenibart. Company remains on track to readout data late next year, and is focused on establishing ex-U.S. partnerships for zaltenibart.
    • 21 Mar 2025 According to an Omeros Corporation media release, Data needed for submission of the biologics licensing application (BLA) and global approval dossiers for zaltenibart in PNH remain on track for the fourth quarter of 2026.
    • 21 Mar 2025 According to an Omeros Corporation media release, A total of 120 clinical investigative sites across 30 countries have been chosen for clinical trial participation in the zaltenibart Phase 3 program in PNH.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top